
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1520336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery, 2012, 2, 227-235.	9.4	852
2	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
3	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications, 2017, 8, 1136.	12.8	686
4	Application of Cell-free DNA Analysis to Cancer Treatment. New England Journal of Medicine, 2018, 379, 1754-1765.	27.0	634
5	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	9.4	448
6	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	1.6	430
7	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	9.4	384
8	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
9	<i>STAT3</i> Plays a Critical Role in <i>KRAS</i> Induced Pancreatic Tumorigenesis. Cancer Research, 2011, 71, 5020-5029.	0.9	358
10	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	7.1	353
11	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 2013, 23, 121-128.	16.8	343
12	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
13	A combinatorial strategy for treating KRAS-mutant lung cancer. Nature, 2016, 534, 647-651.	27.8	337
14	<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation. Science Signaling, 2010, 3, ra84.	3.6	314
15	Targeting Alterations in the RAF–MEK Pathway. Cancer Discovery, 2019, 9, 329-341.	9.4	282
16	Therapeutic strategies to target RAS-mutant cancers. Nature Reviews Clinical Oncology, 2018, 15, 709-720.	27.6	274
17	Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery, 2015, 5, 358-367.	9.4	265
18	Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition. Clinical Cancer Research. 2020. 26. 1633-1643.	7.0	263

#	Article	IF	CITATIONS
19	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	9.4	256
20	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	28.9	256
21	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
22	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	9.4	243
23	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922.	9.4	243
24	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
25	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	7.0	178
26	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation, 2011, 121, 4311-4321.	8.2	177
27	Inhibition of <i>KRAS</i> -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. Cancer Discovery, 2014, 4, 452-465.	9.4	169
28	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <i>MET</i> -Amplified Esophagogastric Cancer. Cancer Discovery, 2015, 5, 1271-1281.	9.4	162
29	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma. Science Translational Medicine, 2013, 5, 196ra98.	12.4	124
30	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 396-404.	7.0	121
31	Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. Oncotarget, 2011, 2, 336-346.	1.8	114
32	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nature Cancer, 2021, 2, 1124-1135.	13.2	112
33	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
34	Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	7.0	79
35	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist, 2019, 24, 1340-1347.	3.7	73
36	Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nature Communications, 2020, 11, 2971.	12.8	71

#	Article	IF	CITATIONS
37	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
38	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research, 2019, 25, 5561-5571.	7.0	64
39	Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 439-449.	7.0	64
40	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> V600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	9.4	61
41	Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Medicine, 2017, 9, 37.	8.2	52
42	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	17.5	48
43	<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery, 2021, 11, 2488-2505.	9.4	46
44	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 719-727.	7.0	46
45	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	7.0	39
46	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
47	Cellâ€free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancer. Cancer, 2022, 128, 2193-2204.	4.1	35
48	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Reports, 2022, 39, 110993.	6.4	34
49	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	3.0	30
50	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discovery, 2022, 12, 1462-1481.	9.4	30
51	Liquid biopsy versus tumor biopsy for clinical-trial recruitment. Nature Medicine, 2020, 26, 1815-1816.	30.7	29
52	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1423172.	4.6	25
53	Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with <i>BRAF</i> Mutation and 5-year Overall Survival. Radiology Imaging Cancer, 2020, 2, e190084.	1.6	22
54	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	2.8	21

#	Article	IF	CITATIONS
55	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	1.4	21
56	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	17
57	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	3.8	17
58	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	3.7	16
59	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	3.0	16
60	Cell-free DNA Analysis in Cancer. New England Journal of Medicine, 2019, 380, 501-502.	27.0	12
61	Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Molecular and Cellular Oncology, 2016, 3, e1048405.	0.7	11
62	Fast-TRKing Drug Development for Rare Molecular Targets. Cancer Discovery, 2017, 7, 934-936.	9.4	9
63	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?. JAMA Oncology, 2020, 6, 823.	7.1	9
64	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist, 2021, 26, e963-e970.	3.7	9
65	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	7.0	8
66	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer, 2021, 127, 619-627.	4.1	7
67	Circulating Tumor DNA: Clinical Monitoring and Early Detection. Annual Review of Cancer Biology, 2019, 3, 187-201.	4.5	6
68	Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Response. Clinical Cancer Research, 2021, 27, 6614-6615.	7.0	4
69	Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast. Cancer Discovery, 2018, 8, 1213-1215.	9.4	3
70	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	3.8	3
71	Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation. Cancer Research, 2022, 82, 5162-5162.	0.9	1
72	Abstract LB003: Combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients: Correlative studies from a phase 2 trial. Cancer Research, 2022, 82, LB003-LB003.	0.9	1